A5022619503- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Advanced biosensing and bioanalysis techniques
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Cutaneous lymphoproliferative disorders research
- Immunotherapy and Immune Responses
- Microfluidic and Capillary Electrophoresis Applications
- Biochemical and Molecular Research
- Genomics and Rare Diseases
- Genomics and Phylogenetic Studies
- Molecular Biology Techniques and Applications
- Genomic variations and chromosomal abnormalities
- Multiple Myeloma Research and Treatments
- Congenital heart defects research
- Inflammasome and immune disorders
- Neutropenia and Cancer Infections
University of Lübeck
2017-2025
University Hospital Schleswig-Holstein
2017-2025
Kiel University
2017-2024
University Medical Center
2019
University College London
2019
Hubei Cancer Hospital
2019
Great Ormond Street Hospital
2019
Charles University
2014-2018
University Hospital in Motol
2013-2017
Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification quantification minimal residual disease (MRD) in lymphoid neoplasms has been the focus intense research, development application. However, standardization validation a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay design, including bioinformatics, was performed within EuroClonality-NGS...
One of the hallmarks B lymphoid malignancies is a cell clone characterized by unique footprint clonal immunoglobulin (IG) gene rearrangements that serves as diagnostic marker for clonality assessment. The EuroClonality/BIOMED-2 assay currently gold standard analyzing IG heavy chain (IGH) and κ light (IGK) suspected lymphomas. Here, EuroClonality-NGS Working Group presents multicentre technical feasibility study novel approach involving next-generation sequencing (NGS) IGH IGK loci highly...
Assessment of clonality, marker identification and measurement minimal residual disease (MRD) immunoglobulin (IG) T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use clinical diagnostics. So far, however, there a lack suitable quality control (QC) options with regard to standardisation metrics ensure robust application such approaches. The EuroClonality-NGS Working Group has therefore...
Abstract Minimal/measurable residual disease (MRD) diagnostics using real-time quantitative PCR analysis of rearranged immunoglobulin and T-cell receptor gene rearrangements are nowadays implemented in most treatment protocols for patients with acute lymphoblastic leukemia (ALL). Within the EuroMRD Consortium, we aim to provide comparable, high-quality MRD diagnostics, allowing appropriate risk-group classification inter-protocol comparisons. To this end, set up a quality assessment scheme,...
Abstract We have shown previously that ETV6/RUNX1 ‐positive acute lymphoblastic leukemia (ALL) is distinguishable from other ALL subtypes by CD27 pos /CD44 low‐neg immunophenotype. During diagnostic immunophenotyping of 573 childhood B‐cell precursor (BCP‐ALL), we identified eight cases with this immunophenotype among “B‐other ALL” (BCP‐ALL negative for routinely tested chromosomal/genetic aberrations). aimed to elucidate whether these belong the recently described ‐like defined ‐specific...
We compared minimal/measurable residual disease (MRD) levels evaluated by routinely used real-time quantitative polymerase chain reaction (qPCR) patient-specific assays and next-generation sequencing (NGS) approach in 780 immunoglobulin (IG) T-cell receptor (TR) markers 432 children with B-cell precursor acute lymphoblastic leukemia treated on the AIEOP-BFM ALL 2009 protocol. Our aim was to compare MRD-based risk stratification at end of induction. The results were concordant 639 (81.9%)...
Abstract Persistence of minimal residual disease (MRD) after induction/consolidation therapy in acute lymphoblastic leukemia is the leading cause relapse. The GMALL 07/2003 study used MRD detection by real-time quantitative polymerase chain reaction clonal immune gene rearrangements with 1 × 10−4 as discriminating cutoff: levels ≥1 define molecular failure and MRD-negativity an assay sensitivity at least defining complete response. clinical relevance results not fitting into these categories...
Detection of measurable residual disease (MRD) in hematological malignancies is crucial for prognostication and treatment decisions.Real-time quantitative PCR (RQ-PCR), which targets immunoglobulin (IG) T-cell receptor (TR) rearrangements, deemed the gold-standard method MRD detection national international clinical trials.However, this approach does have some limitations, primarily related to standard curve performance non-specific background amplification.International guidelines criteria...
DiGeorge syndrome (DGS) presents with a wide spectrum of thymic pathologies. Nationwide neonatal screening programs lymphocyte production using T-cell recombination excision circles (TREC) have repeatedly identified patients DGS. We tested what proportion DGS could be at birth by combined TREC and kappa-deleting element circle (KREC) screening. Furthermore, we followed TREC/KREC levels in peripheral blood (PB) to monitor postnatal changes production.TREC/KREC copies were assessed...
Next-generation sequencing (NGS) has become a mainstream method in bioanalysis. Improvements and bioinformatics turned the complex cumbersome library preparation to bottleneck terms of reproducibility costs complete NGS workflow. Here, we introduce an automated approach based on generic centrifugal microfluidic cartridge. Multiplex polymerase chain reaction amplification subsequent cleanup were performed with all reagents prestored disk, including cell-line-based DNA as quality control....
A recent refinement in high-throughput sequencing involves the incorporation of unique molecular identifiers (UMIs), which are random oligonucleotide barcodes, on library preparation steps. UMI adds a identity to different DNA/RNA input molecules through polymerase chain reaction (PCR) amplification, thus reducing bias this step. Here, we propose an alignment free framework serving as preprocessing step fastq files, called UMIc, for deduplication and correction reads building consensus...